Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.

@article{Kim2002RaloxifeneAM,
  title={Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgen-independent human prostate cancer cell lines.},
  author={Isaac Yi Kim and B Kim and Do Hwan Seong and Dug Keun Lee and Jeong-Meen Seo and Young Jin Hong and Heung-tae Kim and R. R. A. Morton and Seong-Jin Kim},
  journal={Cancer research},
  year={2002},
  volume={62 18},
  pages={5365-9}
}
Raloxifene, a selective estrogen receptor (ER) modulator, is a mixed estrogen agonist/antagonist that has been shown to prevent osteoporosis and breast cancer in women. Because the prostate contains high levels of ER-beta, the present study investigated the effect of raloxifene in three well-characterized, androgen-independent human prostate cancer cell lines: (a) PC3; (b) PC3M; and (c) DU145. Reverse transcriptase-PCR and Western blot analysis for ER-alpha and ER-beta demonstrated that all… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

Similar Papers

Loading similar papers…